Neurochemical predictors of response to pharmacologic treatments for bipolar disorder

Current Psychiatry Reports

Volumn 6, Issue 6, 2004, Pages 466-472

  DelBello, Melissa P ^a   Strakowski, Stephen M ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; ASPARTIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINE; CREATINE PHOSPHATE; CREATININE; DIACYLGLYCEROL; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLYCEROPHOSPHOETHANOLAMINE; GLYCINE; INOSITOL; LACTIC ACID; LITHIUM; MOOD STABILIZER; MUSCARINIC RECEPTOR; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHATASE; PHOSPHATIDYLCHOLINE; PHOSPHODIESTERASE; PHOSPHORUS; PHOSPHOSERINE; PLACEBO; TAURINE; UNINDEXED DRUG; VALPROIC ACID; BIOLOGICAL MARKER; TRANQUILIZER;

BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE MARKER; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; LITHIUM BLOOD LEVEL; LONG TERM CARE; LONGITUDINAL STUDY; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROPROTECTION; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RATING SCALE; REVIEW; TREATMENT OUTCOME; BRAIN LEVEL; PATHOLOGY;

ANTIMANIC AGENTS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN CHEMISTRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PROGNOSIS; TREATMENT OUTCOME;

EID: 16644400371     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-004-0012-1     Document Type: Review

References (58)

1. Lish JD, Dime-Meenan S, Whybrow PC, et al.: The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994, 31:281-294.
2. Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
3. Lewinsohn PM, Klein DN, Seeley JR: Bipolar disorder during adolescence and young adulthood in a community sample. Bipolar Disord 2000, 2:281-293.
4. Frye MA, Ketter TA, Leverich GS, et al.: The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000, 61:9-15.
5. Bhangoo RK, Lowe CH, Myers FS, et al.: Medication use in children and adolescents treated in the community for bipolar disorder. J Child Adolesc Psychopharmacol 2003, 13:515-522.
6. Gelenberg AJ, Pies R: Matching the bipolar patient and the mood stabilizer. Ann Clin Psychiatry 2003, 15:203-216.
7. Bowden CL: Predictors of response to divalproex and lithium. J Clin Psychiatry 1995, 56:25-30.
8. Soares JC, Krishnan KR, Keshavan MS: Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. Depression 1996, 4:14-30.
9. Kato T, Inubushi T, Kato N: Magnetic resonance spectroscopy in affective disorders. J Neuropsychiatry Clin Neurosci 1998, 10:133-147.
10. Post RM, Speer AM, Hough CJ, et al.: Neurobiology of bipolar illness: implications for future study and therapeutics. Ann Clin Psychiatry 2003, 15:85-94.
11. Strakowski SM, DelBello MP, Adler C, et al.: Neuroimaging in bipolar disorder. Bipolar Disord 2000, 2:148-164.
12. Glitz D, Manji H, Moore GJ: Mood disorders: Treatment-induced changes in brain neurochemistry and structure. Semin Clin Neuropsychiatry 2002, 7:269-280.
13. Moore GJ, Galloway MP: Magnetic resonance spectroscopy: Neurochemistry and treatment effects in affective disorders. Psychopharm Bull 2002, 36:5-23.
14. Soares JC, Boada F, Matcheri S, et al.: Brain lithium measurements with (7)Li magnetic resonance spectroscopy (MRS): a literature review. Eur Neuropsychopharmacol 2000, 10:151-158.
15. Strakowski SM, DelBello MP, Adler CM: The functional neuroanatomy of bipolar disorder. Mol Psychiatry. In press.
16. Strakowski SM, Adler CM, DelBello MP: Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder? Bipolar Disord 2002, 4:80-88.
17. Tsai G, Coyle JT: N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995, 46:531-540.
18. Winsberg ME, Sachs N, Tate DL, et al.: Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry 2000, 15:475-481.
19. Cecil KM, DelBello MP, Morey R, et al.: Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord 2002, 4:357-365.
20. Bertolino A, Frye M, Callicott JH, et al.: Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biol Psychiatry 2003, 15:906-913.
21. Deicken RF, Pegues MP, Anzalone S, et al.: Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder. Am J Psychiatry 2003, 160:873-882.
22. Ohara K, Isoda H, Suzuki Y, et al.: Proton magnetic resonance spectroscopy of the lenticular nuclei in bipolar I affective disorder. Psychiatry Res 1998, 84:55-60.
23. Deicken RF, Eliaz Y, Feiwell R, et al.: Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder. Psychiatry Res 2001, 106:35-45.
24. Chang K, Adleman N, Dienes K, et al.: Decreased N-acetylaspartate in children with familial bipolar disorder. Biol Psychiatry 2003, 53:1059-1065.
25. Cecil KM, DelBello MP, Sellars MC, et al.: Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk for bipolar disorders. J Child Adolesc Psychopharmacol 2003, 13:545-555.
26. Sharma R, Venkatasubramanian PN, Barany M, et al.: Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res 1992, 8:43-49.
27. Kato T, Hamakawa H, Shioiri T, et al.: Choline-containing compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder. J Psychiatry Neurosci 1996, 21:248-254.
28. Davanzo P, Thomas MA, Yue K, et al.: Decreased anterior cingulated myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 2001, 24:359-369.
29. Moore GJ, Bebchuk JM, Hasanat K, et al.: Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000, 48:1-8.
30. Brambilla P, Stanley JA, Sassi RB, et al.: 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsycho pharmacology 2004, epub ahead of print on PubMed.
31. Silverstone PH, Wu RH, O'Donnell T, et al.: Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 2003, 18:73-79.
32. DelBello MP, Kowatch RA, Cecil KM, et al.: The neuropathophysiology of adolescent bipolar disorder. Presented at American Academy of Child and Adolescent Psychiatry Annual Meeting. Miami, FL, October, 2003.
33. Hallcher LM, Sherman WR: The effect of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 1980, 255:10896-10901.
34. Moore GJ, Bebchuk JM, Parrish JK, et al.: Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry 1999, 156:1902-1908.
35. Bruhn H, Stoppe G, Staedt J, et al.: Quantitative proton MRS in vivo shows cerebral myo-inositol and choline to be unchanged in manic-depressive patients treated with lithium. Proc Soc Magnetic Resonance Med 1993, (abstract) 1543.
36. Silverstone PH, Wu RH, O'Donnell T, et al: Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. Hum Psychopharmacol 2002, 17:321-327.
37. Moore CM, Breeze JL, Gruber SA, et al.: Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulated cortex. Bipolar Disord 2000, 2:207-216.
38. Silverstone PH, Hanstock CC, Fabian J, et al.: Chronic lithium does not alter human myo-inositol or phosphomonoester concentrations as measured by 1H and 31P MRS. Biol Psychiatry 1996, 15:235-246.
39. Wu RH, O'Donnell T, Ulrich M, et al.: Brain choline concentrations may not be altered in euthymic bipolar disorder patients chronically treated with either lithium or sodium valproate. Ann Gen Hosp Psychiatry 2004, 3: Epub ahead of print.
40. Stoll AL, Renshaw PF, Sachs GS, et al.: The human brain resonance of choline-containing compounds is similar in patients receiving lithium treatment and controls: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 1992, 32:944-949.
41. Lafer B, Renshaw PF, Sachs G, et al.: Proton MRS of the basal ganglia in bipolar patients. Biol Psychiatry 1994, 35 (abstract):68S.
42. Silverstone PH, Hanstock CC, Rotzinger S: Lithium does not alter the choline/creatine ratio in the temporal lobe of human volunteers as measured by proton magnetic resonance spectroscopy. J Psychiatry Neurosci 1999, 24:222-226.
43. Stoll AL, Sachs GS, Cohen BM, et al.: Choline in the treatment of rapid-cycling bipolar disorder: dinical and neurochemical findings in lithium treated patients. Biol Psychiatry 1996, 40:382-388.
44. Lyoo IK, Demopulos CM, Hirashima F, et al.: Oral choline decreases brain purine levels in lithium-treated subjects with rapid cycling bipolar disorder: a double-blind trial using proton and lithium magnetic resonance spectroscopy. Bipolar Disord 2003, 5:300-306.
45. Michael N, Erfurth A, Ohrmann P, et al: Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology 2003, 168:344-346.
46. Dager SR, Friedman SD, Parow A, et al.: Brian metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004, 61:450-458.
47. Castillo M, Kwock L, Courvoisie H, et al.: Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. Am J Neuroradiol 2000, 21:832-838.
48. Preece NE, Gadian DG, Houseman J, et al.: Lithium-induced modulation of cerebral inositol phosphate metabolism in the rat: a multinuclear magnetic resonance study in vivo. Lithium 1992, 3:287-297.
49. Kato T, Inubushi T, Kato N: Prediction of lithium response by 31P-MRS in bipolar disorder. Int J Neuropsychoparmacol 2000, 3:83-85.
50. Renshaw PF, Schnall MD, Leigh Jr JS: In vivo 31P NMR spectroscopy of agonist-stimulated phosphatidylinositol metabolism in cat brain. Magn Reson Med 1987, 4:221-226.
51. Komoroski RA, Newton JE, Walker E, et al.: In vivo NMR spectroscopy of lithium-7 in humans. Magn Reson Med 1990, 15:347-356.
52. Gyulai L, Wicklund SW, Greenstein R, et al.: Measurement of tissue lithium concentration by lithium magnetic resonance spectroscopy in patients with bipolar disorder. Biol Psychiatry 1991, 15:1161-1170.
53. Kato T, Takahashi S, Inubushi T: Brain lithium concentration by 7Li- and 1H- magnetic resonance spectroscopy in bipolar disorder. Psychiatry Res 1992, 45:53-63.
54. Kato T, Shioiri T, Inubushi T, et al.: Brain lithium concentrations measured with lithium-7 magnetic resonance spectroscopy in patients with affective disorders: relationship to erythrocyte and serum concentrations. Biol Psychiatry 1993, 33:147-152.
55. Kato T, Inubushi T, Takahashi S: Relationship of lithium concentrations in the brain measured by lithium-7 magnetic resonance spectroscopy to treatment response in mania. J Clin Psychopharmacol 1994, 14:330-335.
56. Sachs GS, Renshaw PF, Lafer B, et al.: Gonzalez RG: Variability of brain lithium levels during maintenance treatment: a magnetic resonance spectroscopy study. Biol Psychiatry 1995, 38:422-428.
57. Jensen HV, Plenge P, Stensgaard A, et al: Twelve-hour brain lithium concentration in lithium maintenance treatment of manic-depressive disorder: daily versus alternate-day dosing schedule. Psychopharmacology 1996, 124:275-278.
58. Kato T, Fujii K, Shioiri T, et al.: Lithium side effects in relation to brain lithium concentration measured by lithium-7 magnetic resonance spectroscopy. Pro Neuropsychopharmacol Biol Psychiatry 1996, 20:87-97.